Chong Kun Dang Pharmaceutical

This phase 3 trial tests whether a combination pill containing sacubitril and valsartan (CKD-202A) works better than valsartan alone for essential hypertension. About 324 adults with high blood pressure will take either the combo or the standard drug for 10 weeks. The main goal i…

This study tests a new drug called CKD-703 in people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has a specific marker (c-Met). The drug is designed to seek out and destroy cancer cells while sparing healthy ones. The trial has three part…

This Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licens…

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…

This study tests a new drug called CKD-706, which is similar to the approved eczema treatment Dupixent. It involves 519 healthy adults aged 18 to 55. The goal is to see how the body processes the drug and check for side effects, not to treat any disease.